Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-22T08:14:15.385Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of Adult ADHD and Comorbid Disorders

Published online by Cambridge University Press:  07 November 2014

Joel L. Young
Joel L. Young*
Affiliation:
Dr. Young is medical director and founder of the Rochester Center for Behavioral Medicine in Rochester, Michigan. His book, ADHD Grown Up, will be published by WW Norton in late 2006. Dr. Young is a consultant to and speaker for Eli Lilly, Johnson & Johnson, Novartis, and Shire.
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Research Article
Information
CNS Spectrums , Volume 11 , Issue S11 , 2006 , pp. 10 - 12
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kessler, RC. Prevalence of ADHD in American Population. Presented at: Annual Meeting of the American Psychiatric Association; May 2004; New York, NY.Google Scholar
2.American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):1033–1044.CrossRefGoogle Scholar
3.Safren, SA, Otto, MW, Sprich, S, Winett, CL, Wilens, TE, Biederman, J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther. 2005;43(7):831–842.CrossRefGoogle ScholarPubMed
4.Biederman, J, Swanson, JM, Wigal, SB, et al.Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116(6):e777–784.CrossRefGoogle ScholarPubMed
5.Carlson, GA, Kelly, KL. Stimulant rebound: how common is it and what does it mean? J Child Adol Psychopharmacol. 2003;13(2):137–142.CrossRefGoogle ScholarPubMed
6. Srattera [package insert]. Indianapolis, IN: Eli Lilly and Company; 2003.Google Scholar
7.Wilens, TE, Biederman, JB, Mick, E, Spencer, T. A systematic assessment of tricyclic antidepressants in the treatment of attention-deficit/hyperactivity disorder. J Nerv Ment Dis. 1995:183:48–50.CrossRefGoogle ScholarPubMed
8.Wilens, TE, Biederman, J, Prince, J, et al.Six-week, double-blind placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153:1147–1153.Google ScholarPubMed
9.Spencer, T, Biederman, J, Wilens, T. Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatric Clin N Am. 2004;27:373–383.CrossRefGoogle ScholarPubMed
10.Cohen, J. Statistical Power Analysis for the Behavior Sciences. 2nd ed. New York, NY: Lawrence Erlbaum Associates; 1988.Google Scholar
11. Data on file, Shire US Inc., 2006.Google Scholar
12.Shekim, WO, Asarnow, RF, Hess, E, Zaucha, K, Wheeler, N. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry. 1990;31(5):416–425.CrossRefGoogle ScholarPubMed